Keyphrases
Myeloma
100%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
94%
Multiple Myeloma
84%
Allogeneic Bone Marrow Transplantation
81%
Bone Marrow Transplantation
71%
Graft-versus-host Disease (GvHD)
62%
Hematological Malignancies
49%
Acute Myeloid Leukemia
43%
Transplantation
41%
Cyclophosphamide
40%
Marrow
38%
Acute Leukemia
36%
First Remission
36%
Remission
35%
Autograft
35%
Complete Remission
34%
High-dose Melphalan
33%
Stem Cell Transplantation
32%
Hematopoietic Stem Cell Transplantation
32%
Overall Survival
31%
Chemotherapy
31%
CD34+
31%
Allograft
30%
Melphalan
30%
Granulocyte Colony-stimulating Factor (G-CSF)
29%
Autotransplantation
28%
Allogeneic Transplantation
27%
Peripheral Blood Stem Cells
26%
Thalidomide
24%
Autologous Transplantation
24%
Engraftment
23%
Cyclosporine
22%
CD34+ Cells
22%
Graft-versus-leukemia Effect
22%
High-dose Chemotherapy
22%
High-dose Therapy
22%
Disease-free Survival
22%
Autografting
21%
Peripheral Blood
21%
Interferon-α (IFN-α)
21%
High Dose
20%
Etoposide
20%
Unrelated Donor
19%
Total Body Irradiation
19%
Leukemia Patients
19%
Relapsed or Refractory Acute Myeloid Leukemia
18%
Stem Cells
18%
Cell Dose
18%
Allogeneic
18%
Adult Patients
18%
Medicine and Dentistry
Myeloma
74%
Multiple Myeloma
56%
Drug Megadose
54%
Diseases
52%
Bone Marrow Transplantation
46%
Allogenic Bone Marrow Transplantation
44%
Melphalan
44%
Acute Leukemia
42%
Autotransplantation
40%
Allograft
38%
Acute Myeloid Leukemia
36%
Hematologic Malignancy
36%
Graft Versus Host Reaction
35%
Autograft
35%
Hematopoietic Stem Cell Transplantation
34%
Overall Survival
30%
Cyclophosphamide
25%
Peripheral Blood Stem Cell
23%
Stem Cell Therapy
23%
Conditioning
23%
Infection
22%
Hematopoietic Cell
22%
Stem Cell
21%
Acute Lymphoblastic Leukemia
20%
Autologous Hematopoietic Stem Cell Transplantation
19%
Autologous Bone Marrow Transplantation
19%
Cyclosporine
18%
Disease Free Survival
17%
High Dose Chemotherapy
17%
Malignant Neoplasm
16%
Stem Cell Transplant
16%
Arsphenamine
16%
Engraftment
15%
Allogeneic Hematopoietic Stem Cell Transplantation
15%
Maintenance Chemotherapy
15%
Immunotherapy
14%
Leukemia
14%
Mycosis
13%
B-Cell Chronic Lymphocytic Leukemia
13%
Adverse Event
13%
Thalidomide
13%
Spontaneous Remission
13%
Karyotype
13%
T Cell
13%
Cytarabine
12%
Methotrexate
12%
Platelet
12%
Amphotericin B Lipid Complex
12%
Event Free Survival
11%
Whole Body Radiation
11%
Immunology and Microbiology
Bone Marrow Transplantation
69%
Multiple Myeloma
66%
Drug Megadose
64%
Allograft
50%
CD34
50%
Graft-Versus-Host Disease
47%
Myeloid
39%
Allogeneic Bone Marrow Transplantation
38%
Overall Survival
35%
Cyclophosphamide
32%
Allogeneic Hematopoietic Stem Cell Transplantation
32%
Peripheral Blood Stem Cell
30%
Hematopoietic Stem Cell Transplantation
27%
Stem Cell
27%
Autotransplantation
26%
Stem Cell Transplantation
25%
Engraftment
24%
Conditioning
24%
Ciclosporin
22%
Autograft
22%
Neutrophil
20%
Thalidomide
20%
Hematopoietic Cell
20%
Immunotherapy
18%
Disease Free Survival
18%
Chronic Graft Versus Host Disease
17%
Autologous Hematopoietic Stem Cell Transplantation
16%
Event Free Survival
16%
Interferon Type I
14%
Platelet
12%
Blood Plasma
12%
Granulocyte Colony-Stimulating Factor
12%
Methylprednisolone
12%
Leukocyte
12%
T Cell
12%
Stem Cell Transplant
11%
Cell Count
11%
Leukapheresis
10%
Acute Graft Versus Host Disease
10%
Myeloma Protein
10%
Body Weight
10%
Apheresis
9%
Syngenic
9%
Methotrexate
9%
Kidney Function
9%
Leukocyte Count
8%
Neutrophil Count
7%
Immunosuppression
7%
Growth Factor
6%
Immunoglobulin A
6%